Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | GFER | P55789 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | KDM1A | O60341 | 1/20 | 0.57 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KLK7 | P49862 | 1/20 | 0.51 |
| ▸ | PREP | P48147 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10082579 | 0.94 | GFER (0.61) | ALDH1A1GFERTSHRL3MBTL1KMT2A | |
| SCHEMBL12332120 | 0.90 | ALDH1A1 (0.65) | ALDH1A1GFERTSHRL3MBTL1KMT2A | |
| SCHEMBL17055670 | 0.88 | GFER (0.64) | ALDH1A1GFERTSHRL3MBTL1KMT2A | |
| SCHEMBL4387231 | 0.88 | ALDH1A1 (0.65) | ALDH1A1GFERTSHRL3MBTL1KMT2A | |
| SCHEMBL13588905 | 0.88 | ALDH1A1 (0.65) | ALDH1A1GFERTSHRL3MBTL1KMT2A | |
| SCHEMBL10222796 | 0.88 | GFER (0.64) | ALDH1A1GFERTSHRL3MBTL1KMT2A | |
| SCHEMBL3208219 | 0.87 | GFER (0.79) | ALDH1A1GFERTSHRL3MBTL1KMT2A | |
| SCHEMBL3216457 | 0.87 | GFER (0.79) | ALDH1A1GFERTSHRL3MBTL1KMT2A | |
| SCHEMBL13424972 | 0.86 | GFER (0.69) | ALDH1A1GFERTSHRL3MBTL1KMT2A | |
| SCHEMBL13456105 | 0.85 | TSHR (0.66) | ALDH1A1GFERTSHRL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2900656-B1 | SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | SUNSHINE LAKE PHARMA CO LTD (CN) | 2017-05-17 | — | — | EP | disclosed |
| US-9416139-B2 | Spiro ring compound as hepatitis C virus (HCV) inhibitor and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-08-16 | — | — | US | disclosed |
| US-9309231-B2 | Bridged ring compounds as hepatitis C virus (HCV) inhibitors and pharmaceutical applications thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-04-12 | — | — | US | disclosed |
| US-20150232509-A1 | SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-08-20 | — | — | US | disclosed |
| US-20150079028-A1 | Bridged Ring compounds As Hepatitis C Virus (HCV) Inhibitors And Pharmaceutical Applications Thereof | SUNSHINE LAKE PHARMA CO., LTD (CN) | 2015-03-19 | — | — | US | disclosed |
| US-8815849-B2 | Hetero-bicyclic derivatives as HCV inhibitors | JANSSEN R&D IRELAND (IE) | 2014-08-26 | — | — | US | disclosed |
| US-8815849-B2 | Hetero-bicyclic derivatives as HCV inhibitors | JANSSEN R&D IRELAND (IE) | 2014-08-26 | — | — | US | disclosed |
| EP-2598498-B1 | HETERO-BICYCLIC DERIVATIVES AS HCV INHIBITORS | JANSSEN R & D IRELAND (IE) | 2014-07-09 | — | — | EP | disclosed |
| WO-2014019344-A1 | BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS AND PHARMACEUTICAL APPLICATIONS THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-02-06 | — | — | WO | disclosed |
| US-20130123244-A1 | Hetero-Bicyclic Derivatives as HCV Inhibitors | JANSSEN R&D IRELAND (IL) | 2013-05-16 | — | — | US | disclosed |
| US-20130123244-A1 | Hetero-Bicyclic Derivatives as HCV Inhibitors | JANSSEN R&D IRELAND (IL) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232509-A1 | SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | HAVCR2, SLC10A1, SORD | ALDH1A1 588/4885GFER 441/4885TSHR 2665/4885 |
| US-20150079028-A1 | Bridged Ring compounds As Hepatitis C Virus (HCV) Inhibitors And Pharmaceutical Applications Thereof | SLC10A1, HAVCR2, UGT1A3 | ALDH1A1 464/4885GFER 338/4885TSHR 4285/4885 |
| US-20130123244-A1 | Hetero-Bicyclic Derivatives as HCV Inhibitors | HAVCR2, ZC3HAV1, SUB1 | ALDH1A1 1768/4885GFER 2487/4885TSHR 4569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.